Former President and Chief Executive Officer · Century Therapeutics, Inc. (IPSC)

Osvaldo Flores

A named executive officer of Century Therapeutics in every fiscal year CompBrief holds from FY2020 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$4,978,394

Salary $176,008Stock awards $0

FY2022: $3,577,315

1st of 5 named executive officers at Century Therapeutics by FY2023 total.

5 named officers on file for Century Therapeutics, FY2023

Osvaldo Flores’s pay file — $29

  • 4 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Century Therapeutics’s whole pay program stands against its peers

  • Century Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on IPSC→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2024 (DEF 14A).

Free

Get Osvaldo Flores’s full pay file as a PDF — free

More than this page: up to 10 years of Osvaldo’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Osvaldo Flores compensation by year

Century Therapeutics Summary Compensation Table · all 4 fiscal years held
In US dollars, as Century Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021FY2022FY2023
Salary$461,250$519,313$580,208$176,008
Bonus$0$0$0$0
Stock awards$0$0$0$0
Option awards$741,750$3,539,110$2,707,003$4,188,293
Non-equity incentive$185,400$258,745$290,104$0
Pension and deferred compensation$0$0$0—
All other$0$0$0$634,093
Total$1,388,400$4,317,168$3,577,315$4,978,394

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Century Therapeutics, Inc. DEF 14A filed April 26, 2024, accession 0001104659-24-052924, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Century Therapeutics, Inc. filed document, accession 0001104659-24-052924. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2024.

$1.4M
$4.3M
$3.6M
$5.0M
FY20
FY21
FY22
FY23
SalaryNon-equity incentiveOption awardsAll other

Century Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Osvaldo Flores · this pageFormer President and Chief Executive Officer$4,978,394
Brent PfeiffenbergerPresident and Chief Executive Officer$3,235,011
Gregory RussottiChief Technology and Manufacturing Officer and former Interim President and Chief Executive Officer$2,589,630
Michael Diemformer Chief Financial Officer$2,225,839
Adrienne FaridChief Operations Officer$1,709,916

The full Century Therapeutics compensation record

free company brief

This page is one person within Century Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Century Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Osvaldo Flores's compensation dossier · One-time report. No refunds.